<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033132</url>
  </required_header>
  <id_info>
    <org_study_id>C-750-CN01</org_study_id>
    <nct_id>NCT05033132</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Balstilimab Independently or in Combination With Zalifrelimab in Cervical Cancer</brief_title>
  <official_title>A Phase 2 Trial of Balstilimab as a Monotherapy or Combination Therapy With Zalifrelimab in Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agenus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Betta Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Agenus Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy&#xD;
      ,safety and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination&#xD;
      with Zalifrelimab (Treatment Arm 2- combination therapy) for treatment of patients with&#xD;
      advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency, severity and duration of treatment-emergent AEs</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Balstilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balstilimab monotherapy approximately 80 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balstilimab + Zalifrelimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balstilimab in combination with Zalifrelimab (combination therapy): approximately 80 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balstilimab</intervention_name>
    <description>Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody</description>
    <arm_group_label>Balstilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balstilimab + Zalifrelimab</intervention_name>
    <description>A PD-1 antibody in combination with a CTLA-4 antibody.</description>
    <arm_group_label>Balstilimab + Zalifrelimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily agree to participate by giving written informed consent.&#xD;
&#xD;
          -  Be ≥18 years of age.&#xD;
&#xD;
          -  Diagnosis:&#xD;
&#xD;
               1. Have a histologically or cytologically confirmed diagnosis of squamous-cell&#xD;
                  carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix, and&#xD;
                  metastatic, locally advanced, and/or unresectable disease at the time of&#xD;
                  enrollment.&#xD;
&#xD;
                  Note: The following cervical tumors are not eligible: minimal deviation/adenoma&#xD;
                  malignum, gastric type adenocarcinoma, clear cell carcinoma, and mesonephric&#xD;
                  carcinoma.&#xD;
&#xD;
               2. Has cervical cancer and has relapsed after a platinum based treatment (first&#xD;
                  line) regimen for advanced (recurrent, unresectable, or metastatic) disease;&#xD;
&#xD;
               3. PD-L1 positive(CPS≥1).&#xD;
&#xD;
          -  Have measurable disease on imaging based on RECIST version 1.1.&#xD;
&#xD;
          -  Have a life expectancy of at least 3 months.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Have adequate organ function as indicated by the following laboratory values:&#xD;
&#xD;
               1. Adequate hematological function defined by absolute neutrophil count (ANC) &gt; 1.5&#xD;
                  x 10^9/L, platelet count &gt; 100 x 10^9/L, and hemoglobin &gt;8 g/dL (without&#xD;
                  transfusions within 1 week of first dose).&#xD;
&#xD;
               2. Adequate hepatic function based by a total bilirubin level ≤ 1.5 the&#xD;
                  institutional upper limit of normal (ULN), aspartate aminotransferase (AST) level&#xD;
                  ≤ 2.5 x ULN, alanine aminotransferase (ALT) level ≤ 2.5 x ULN, and alkaline&#xD;
                  phosphatase ≤ 2.5 x ULN.&#xD;
&#xD;
               3. Adequate renal function defined as creatinine ≤ 1.5 × upper limit of normal (ULN)&#xD;
                  OR measured and calculated creatinine clearance ≥50 mL/minute per Institutional&#xD;
                  standard.&#xD;
&#xD;
               4. Adequate coagulation defined by international normalized ratio (INR) or&#xD;
                  prothrombin time ≤ 1.5 x ULN (unless the patient is receiving anticoagulant&#xD;
                  therapy); and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (unless&#xD;
                  the patient is receiving anticoagulant therapy).&#xD;
&#xD;
          -  Has no history of another primary malignancy with no known active disease ≥5 years&#xD;
             before the first dose of study drug, with the exception of adequately treated&#xD;
             non-melanoma skin cancer , lentigo maligna or superficial bladder cancer.&#xD;
&#xD;
          -  Patients must provide a sufficient and adequate FFPE tumor tissue sample preferably&#xD;
             from the most recent biopsy of a tumor lesion, collected either at the time of or&#xD;
             after the diagnosis of advanced or metastatic disease has been made AND from a site&#xD;
             not previously irradiated. If no tumor tissue is available, a fresh biopsy will be&#xD;
             required.&#xD;
&#xD;
          -  Patients must have a negative serum pregnancy test at screening (within 7 days of&#xD;
             first dose of study medication) if of childbearing potential or be of non-child&#xD;
             bearing potential. Non-childbearing potential is defined as (by other than medical&#xD;
             reasons):&#xD;
&#xD;
               1. ≥45 years of age and has not had menses for greater than 1 year,&#xD;
&#xD;
               2. Amenorrheic ≥ 2 years without a hysterectomy and oophorectomy and a&#xD;
                  follicle-stimulating hormone (FSH) value in the postmenopausal range upon&#xD;
                  pretrial (screening) evaluation,&#xD;
&#xD;
               3. History of hysterectomy, oophorectomy or tubal ligation.&#xD;
&#xD;
          -  If of childbearing potential, female patients must be willing to use adequate barrier&#xD;
             methods throughout the study, starting with the screening visit through 12 months&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
          -  Is willing and able to comply with the requirements of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigation device&#xD;
             within 4 weeks of the first dose of treatment.&#xD;
&#xD;
          -  Has an inadequate washout period prior to first dose of study drug defined as:&#xD;
&#xD;
               1. Received systemic cytotoxic chemotherapy or biological therapy within 3 weeks&#xD;
                  before first dose, or,&#xD;
&#xD;
               2. Received radiation therapy within 3 weeks before first dose, or,&#xD;
&#xD;
               3. Had major surgery within 4 weeks before first dose.&#xD;
&#xD;
          -  Has received prior therapy with Any antibody/drug targeting T-cell co-regulatory&#xD;
             proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, anti-cytotoxic&#xD;
             T-lymphocyte antigen 4 (CTLA-4) antibodies or Lag3.&#xD;
&#xD;
          -  Is expected to require any other form of systemic or localized antineoplastic therapy&#xD;
             while on trial (including maintenance therapy with another agent, radiation therapy,&#xD;
             and/or surgical resection).&#xD;
&#xD;
          -  Has known severe hypersensitivity reactions to fully human monoclonal antibodies&#xD;
             (NCI-CTCAE Grade ≥3).&#xD;
&#xD;
          -  Received hematopoietic stimulating factor treatment within 7 days (≤ 7 days) before&#xD;
             the first dose, such as granulocyte colony stimulating factor (G-CSF), erythropoietin,&#xD;
             etc.&#xD;
&#xD;
          -  Has a central nervous system (CNS) tumor, metastasis(es), and/or carcinomatous&#xD;
             meningitis identified either on the baseline brain imaging obtained during the&#xD;
             screening period OR identified prior to consent.&#xD;
&#xD;
        Note: Patients with history of brain metastases that have been treated may participate&#xD;
        provided they show evidence of stable supra-tentorial lesions at screening (based on 2 sets&#xD;
        of brain images, performed ≥ 4 weeks apart, and obtained after the brain metastases&#xD;
        treatment). In addition, any neurologic symptoms that developed either as a result of the&#xD;
        brain metastases or their treatment must have resolved or be minimal and be expected as&#xD;
        sequelae from treated lesions. For individuals who received steroids as part of brain&#xD;
        metastases treatment, steroids must be discontinued ≥ 7 days prior to first dose of study&#xD;
        drug.&#xD;
&#xD;
        -Has active or history of autoimmune disease that has required immunosuppressive systemic&#xD;
        treatment within 2 years of the start of trial treatment (i.e. with use of disease&#xD;
        modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (i.e.,&#xD;
        thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or&#xD;
        pituitary insufficiency, etc.) is not considered a form of immunosuppressive systemic&#xD;
        treatment.&#xD;
&#xD;
        Note: Patients with diabetes type 1, vitiligo, psoriasis, hypothyroidism, or hyperthyroid&#xD;
        disease not requiring immunosuppressive treatment are eligible.&#xD;
&#xD;
          -  Has had an allogeneic tissue/solid organ transplant.&#xD;
&#xD;
          -  Has or had interstitial lung disease (ILD) OR has had a history of pneumonitis that&#xD;
             has required oral or intravenous corticosteroids.&#xD;
&#xD;
          -  Has an active infection requiring intravenous systemic therapy.&#xD;
&#xD;
          -  Has known history of Human Immunodeficiency Virus (HIV) or treponema pallidum.&#xD;
&#xD;
          -  Has known active Hepatitis B (HBV), Hepatitis C (HCV), or tuberculosis.Active&#xD;
             Hepatitis B is defined as a known positive HBsAg or HBcAb result. Active Hepatitis C&#xD;
             is defined by a known positive Hep C Ab result and known quantitative HCV ribonucleic&#xD;
             acid (RNA) results greater than the lower limits of detection of the assay.&#xD;
&#xD;
          -  Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular&#xD;
             accident/stroke or myocardial infarction within 6 months of enrollment, unstable&#xD;
             angina, congestive heart failure (New York Heart Association class ≥II), or serious&#xD;
             uncontrolled cardiac arrhythmia requiring medication, cerebrovascular accident,&#xD;
             transient ischemic attack, cerebral embolism.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the patient's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the patient to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  Has known psychiatric that would interfere with cooperation with the requirements of&#xD;
             the trial.&#xD;
&#xD;
          -  Has a history of substance abuse, alcoholism or other addictions.&#xD;
&#xD;
          -  Is legally incapacitated or has limited legal capacity.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Agenus Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agenus, Inc. Clinical Trial Information</last_name>
    <phone>781-674-4265</phone>
    <email>clinicaltrialinfo@agenusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Betta Clinical Study Site 4</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Sun</last_name>
      <phone>0552-3085746</phone>
      <email>ahbbsr@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 2</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yueyin Pan</last_name>
      <phone>0551-62283666</phone>
      <email>yueyinpan1965@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 3</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhendong Chen</last_name>
      <phone>0551-65997421</phone>
      <email>ay2fychenzhendong@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 27</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <zip>241001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yiping Zhu</last_name>
      <phone>0553-5738200</phone>
      <email>zhuyiping@wnmc.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 25</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yumei Wu</last_name>
      <phone>010-85968227</phone>
      <email>wym597118@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 42</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qi Zhou</last_name>
      <phone>023-65075695</phone>
      <email>qizhou9128@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 9</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mei Feng</last_name>
      <phone>0591-62752500</phone>
      <email>Conan12221@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 22</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaling Tang</last_name>
      <phone>0592-2137572</phone>
      <email>TYLapple@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 39</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shuping Li</last_name>
      <phone>0931-8281401</phone>
      <email>13321200330@189.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 14</name>
      <address>
        <city>Huizhou</city>
        <state>Guangdong</state>
        <zip>516001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Yuan</last_name>
      <phone>0752-2288848</phone>
      <email>jndx23207@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 18</name>
      <address>
        <city>Meizhou</city>
        <state>Guangdong</state>
        <zip>514031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Li</last_name>
      <phone>0753-2131693</phone>
      <email>liliang@mzrmyy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 10</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sihai Liao</last_name>
      <phone>0759-2369313</phone>
      <email>liaosihai163@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 11</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jieqing Zhang</last_name>
      <phone>0771-5778582</phone>
      <email>1583825050@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 5</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <zip>061001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enfeng Zhao</last_name>
      <phone>0317-2079321</phone>
      <email>13513276821@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 40</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunyan Zhang</last_name>
      <phone>0451-85718577</phone>
      <email>zhangyunyan-1972@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 41</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qinghua Zhang</last_name>
      <phone>027-82201756</phone>
      <email>zhangqh66@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 28</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiping Tao</last_name>
      <phone>027-88041911</phone>
      <email>taowpwp@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 12</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Huang</last_name>
      <phone>027-87670003</phone>
      <email>huangyt32@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 29</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Qiu</last_name>
      <phone>027-67813097</phone>
      <email>qiuhuiznyy@whu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 31</name>
      <address>
        <city>Xiangyang</city>
        <state>Hubei</state>
        <zip>441021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Quan Li</last_name>
      <phone>0710-2811523</phone>
      <email>124993699@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 6</name>
      <address>
        <city>Changde</city>
        <state>Hunan</state>
        <zip>415003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Wu</last_name>
      <phone>0736-7788427</phone>
      <email>20689452@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 36</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Zhu</last_name>
      <phone>0731-89753403</phone>
      <email>zhuhong0719@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 35</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianling Liu</last_name>
      <phone>0731-85292097</phone>
      <email>doctor_xianlingl@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 13</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Wang</last_name>
      <phone>0731-88651669</phone>
      <email>wangjing0081@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 21</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijing Zhu</last_name>
      <phone>025-83105910</phone>
      <email>zhulj@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 8</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunlang Cai</last_name>
      <phone>025-83272064</phone>
      <email>ylseu63@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 38</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yili Wang</last_name>
      <phone>0797-8685619</phone>
      <email>wyllzt@aliyun.Com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 19</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiongyu Lan</last_name>
      <phone>0791-86300985</phone>
      <email>flylanhuacao@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 20</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiuhong Tian</last_name>
      <phone>0791-88695051</phone>
      <email>enanchang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 24</name>
      <address>
        <city>Shangrao</city>
        <state>Jiangxi</state>
        <zip>334000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kairong Huang</last_name>
      <phone>0793-8100658</phone>
      <email>huangkairong123@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 16</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ziling Liu</last_name>
      <phone>0431-88782015</phone>
      <email>784127818@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 15</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiejun Wang</last_name>
      <phone>0431-81136590</phone>
      <email>m13943016598@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 7</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kui Jiang</last_name>
      <phone>0411-84750853</phone>
      <email>jk0411@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 34</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingfang Zhao</last_name>
      <phone>024-832833921</phone>
      <email>Zhaomf618@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 17</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110046</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunyan Wang</last_name>
      <phone>024-31916651</phone>
      <email>lwwcytt@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 30</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruifang An</last_name>
      <phone>029-85324094</phone>
      <email>anruifang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 23</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuqing Wei</last_name>
      <phone>0351-4651692</phone>
      <email>weishuqing1972@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 26</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Chen</last_name>
      <phone>022-23340123</phone>
      <email>tjcjvip@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 37</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ke Wang</last_name>
      <phone>022-23340123</phone>
      <email>18622080116@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 32</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gulina Kurb</last_name>
      <phone>0991-7819430</phone>
      <email>gulinakurb@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betta Clinical Study Site 33</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuejun Chen</last_name>
      <phone>0571-89713634</phone>
      <email>2303011@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lingying Wu, MD</last_name>
      <phone>010-87788996</phone>
      <email>wulingying@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Lingying Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

